Daptomycin + Vancomycin
ApprovedTerminated 1 views this week 0 watching💤 Quiet
Interest: 35/100
35
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Staphylococcal Infections
Conditions
Staphylococcal Infections, Methicillin-resistant Staphylococcus Aureus
Trial Timeline
Oct 1, 2010 → Mar 1, 2014
NCT ID
NCT01196169About Daptomycin + Vancomycin
Daptomycin + Vancomycin is a approved stage product being developed by Merck for Staphylococcal Infections. The current trial status is terminated. This product is registered under clinical trial identifier NCT01196169. Target conditions include Staphylococcal Infections, Methicillin-resistant Staphylococcus Aureus.
What happened to similar drugs?
3 of 4 similar drugs in Staphylococcal Infections were approved
Approved (3) Terminated (1) Active (1)
Hype Score Breakdown
Clinical
20
Activity
0
Company
15
Novelty
0
Community
0
Clinical Trials (6)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01419184 | Approved | Completed |
| NCT01196169 | Approved | Terminated |
| NCT01175707 | Approved | Terminated |
| NCT00695903 | Phase 2 | Terminated |
| NCT00426933 | Phase 2 | Completed |
| NCT00295178 | Approved | Completed |
Competing Products
20 competing products in Staphylococcal Infections